In vitro effect of Dovitinib (TKI258), a multi-target angiokinase inhibitor on aggressive meningioma cells.

CONCLUSIONS: This study establishes the groundwork for development of Dovitinib as a therapeutic agent for high-grade AM with either frequent codeletion or mutated CHEK2 and NF2, an avenue with high translational potential. PMID: 32441531 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research